According to the statistical data, the rate of intracranial hemorrhage was significantly higher in the high-dose ADAMTS-5 inhibitor treatment group than in the low-dose group and DMSO-treatment control group (Figure 7D). The gene discussed is ADAMTS5; the disease is intracranial hemorrhage.